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The aim o f the present study was to determine the in-vitro susceptibility o f  
Toxoplasma gondii to dihydrofolate reductase inhibitors and sulphonamides alone, 
and in combination. It was found that pyrimethamine had the most potent 
anii-Toxoplasma  activity, while sulphadiazine, sulphamethoxazole and sul- 
phametrole were approximately equally effective, but only at a high concentration.
The 50% inhibitory concentration o f sulphamethoxazole was determined using 
different fixed concentrations o f  pyrimethamine or trimethoprim. It was found that 
a ten-fold increment o f  the concentration o f  pyrimethamine, reduced the IC50 o f  
sulphamethoxazole 1000 times. The influence o f trimethoprim on the IC50 of  
sulphamethoxazole was less concentration dependent. Addition o f dihydrofolate 
or tetrahydrofolate did not influence the IC50 o f pyrimethamine. In conclusion, 
the present dose recommendations for sulphonamides, when combined with 
pyrimethamine, may be unnecessarily high. There may be a justification for dose 
reduction o f sulphonamides in order to prevent side effects.
Introduction
Cerebral toxoplasmosis is a common opportunistic infection in patients infected with 
human immunodeficiency virus (HIV) (Schärtlander et a l 1992). The combination of 
pyrimethamine and sulphadiazine is the standard treatment, with documented efficacy 
for Toxoplasma encephalitis. However, the use of this combination is hampered by the 
frequent occurrence of adverse reactions in HIV-seropositive individuals (Haverkos, 
1987; Wanke et a l 1987; Leport et al., 1988; Danneman et al., 1992). Side-effects, 
especially rash and fever, occur in up to 60% of the AIDS patients treated with a 
sulphonamide. Pyrimethamine is mostly associated bone marrow depression (Jacobsen 
et a l 1992, 1994), but this toxicity may be prevented or reversed by the concomitant 
use of folinic acid (Frenkel et a l 1957; DePaillerets et a l 1975). The incidence of these 
adverse reactions is dose dependent, both for sulphonamides and pyrimethamine 
(Leport et al., 1988; van der Ven et a l 1991). It is therefore important to select the 
lowest possible doses for treatment in HIV infected patients.
Sulphadiazine and pyrimethamine exert their effect on two different steps in folic 
acid metabolism. Sulphonamides function as anti-metabolites for dihydropteroate
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synthetase (DHPS), while pyrimethamine is an inhibitor of dihydrofolate reductase 
(DHFR) (Hitchings, 1973; Allegra et al., 1990). Trimethoprim is another DHFR 
inhibitor and the combination with sulphamethoxazole is used in HIV-seropositive 
patients for the treatment and prophylaxis of Pneumocystis carinii pneumonia. This 
combination also has an anti-Toxoplasma effect (Grossman & Remington, 1979; Carr 
et al., 1992). Trimethoprim is also available in combination with sulphametrole but less 
is known about this formulation. Sulphametrole has been associated with less toxicity, 
especially in patients with glucose-6-phosphate dehydrogenase deficiency (Plummer 
et al., 1983). Unlike DHPS, D H FR is present both in T. gondii and mammalian cells, 
but the affinity of pyrimethamine for Toxoplasma D H FR is much higher compared with 
mammalian DHFR. Mammalian cells possess a carrier-mediated active transport 
system responsible for the uptake of preformed folates, while T. gondii lacks this system 
(Allegra et al., 1987).
The aim of the present study was to determine the susceptibility of T. gondii to D H FR 
inhibitors and sulphonamides alone and in combination. We also addressed the 
question to what extent a dose increase of pyrimethamine could lead to a reduction of 
the sulphonamide dose with similar anti-Toxoplasma effect. Since higher dosages of 
D H FR inhibitor could possibly require the use of folinic acid, the influence of folinic 
acid was also studied.
Materials and methods
The in-vitro tests were performed as described elsewhere (Schoondermark-van de Ven 
et al., 1995). Briefly, confluent HEp-2 cells were prepared in 96-well tissue culture plates 
(Costar, Cambridge, MA, USA). At the start of the assay, T. gondii parasites of the 
RH strain were transferred to fresh culture medium with or without antimicrobial 
agents at a concentration of 105 parasites per mL. The HEp-2 cells were overlaid with 
150 pL  of the parasite suspension (parasite-to-cell ratio, 0.7), and incubated in air with 
5% CO: at 90% humidity and 36 C for 90 h. Each test included eight wells without 
parasites and eight wells with parasites but no drugs. Each drug concentration was 
tested eight-fold, and each test was performed three times. After incubation, parasite 
growth was quantified using an enzyme-linked immunosorbent assay, which was 
performed directly on T. go/7^ //-infected HEp-2 cells, as described before 
(Schoondermark-van de Ven et al., 1995). After incubation with human antiserum 
against T. gondii, horseradish peroxidase-labeled rabbit anti-human immunoglobulin 
(Dakopatts, Kopenhagen, Denmark) was added and the colour reaction with 
o-phenylenediamine (Sigma, St Louis, MO) with perhydrol 30% H :0 :  (Merck, 
Darmstadt, Germany) was quantified in a spectrophotometer.
Pyrimethamine and trimethoprim were obtained from Wellcome (Kent, England), 
sulphadiazine from OPG (Utrecht, the Netherlands), sulphamethoxazole from Hoffman 
laRoche (Basel, Switzerland), and sulphametrole from Nycomed (Vienna, Austria).
The 50% inhibitory concentrations ( I C 5o) were determined by testing the drugs at the 
following concentrations: pyrimethamine: 5, 1, 0.5. 0.4, 0.3, 0.2, 0.1, 0.075, 0.05 and 
0.01 mg/L; trimethoprim: 100, 50, 20, 15, 10, 5, 2, 1, 0.5 and 0.1 mg/L; and 
sulphadiazine, sulphamethoxazole and sulphametrole: 1000, 900, 800, 700, 600, 500, 
400, 300, 200 and 100 mg/L. The I C 5o of sulphamethoxazole was also determined in 
combination with a fixed dose of pyriethamine and trimethoprim. In these experiments,
the concentrations of pyrimethamine were 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.025, 0.05,
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Table. In-vitro effect (50% inhibitory 
concentrations) o f  different drugs on
T. gondii
ICS„
(mg/L)
Trimethoprim 5-10
Pyrimethamine 0.2
Sulphadiazine 600-700
Sulphamethoxazole 400-500
Sulphametrole 600-700
0.1, 0.15, 0.2, 0.4 mg/L, and trimethoprim concentrations were 0.5, 1, 2, 3, 4, 5, 6 , 7,
8 , 9 10 mg/L. The corresponding IC5o of sulphamethoxazole was quantified by testing 
sulphamethoxazole at the following concentrations: 200, 100, 50, 20, 10, 5, 1, 0.5, 0.5, 
0.1, 0.05, 0.01, 0.005, 0.001, 0.0005, 0.0001, 0.00005 mg/L. The addition of 0.3 mg/L or
1 mg/L tetrahydrofolate, or 1 mg/L dihydrofolate to the culture medium was also 
studied for the effects on the I C 5o of pyrimethamine.
Results
The IC50 of pyrimethamine, trimethoprim and the three sulphonamides is given in 
the Table. It was found that pyrimethamine has the most potent anû-Toxoplasma 
activity and trimethoprim was approximately 25-50 times less active in vitro. The 
sulphonamides were about equally active but on a weight basis are 40-3500 times less 
active compared with the tested D H FR  inhibitors. Sulphamethoxazole was used to test 
the combination with a D H FR  inhibitor. Figure (a) presents the IC50 of 
sulphamethoxazole in combination with various concentrations of pyrimethamine and 
trimethoprim, and shows that a ten-fold increment of the concentration of 
pyrimethamine reduced the IC50 of sulphamethoxazole 1000 times. Figure (b) 
demonstrates that the anti -Toxoplasma effect of the combination trimethoprim-sul- 
phamethoxazole was not as dose related. The addition of tetrahydrofolate or
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dihydrofolate to the culture medium did not change the IC50 for pyrimethamine (data 
not shown).
Discussion
All the tested compounds possessed antimicrobial activity against T. gondii but the 
highest in-vitro activity was observed using D H FR inhibitors and in particular 
pyrimethamine. IC50 and attainable plasma concentrations may, however, only be 
compared cautiously. The IC50 of pyrimethamine (0.2 mg/L) in this in-vitro system is 
in the range of plasma concentrations obtained after a once weekly dose of 75 mg 
pyrimethamine (Opravil et al., 1994). Trimethoprim has a higher IC50 (5-10 mg/L) and 
concentrations in this range are only reached when patients are treated with the 
relatively high dose of trimethoprim of 20 mg/kg body weight daily (Hart et al., 1991). 
The IC50S of the three sulphonamides are all within the same range and are well above 
the concentrations found in patients treated with a high dose of sulphonamides of 
100 mg/kg body weight daily (Hart et al., 1991).
The IC50 of sulphamethoxazole of 500 mg/L was reduced considerably when a 
DHFR inhibitor was added to the incubation medium. The addition of 0.005 mg/L 
pyrimethamine reduced the IC50 of sulphamethoxazole to 50 mg/L, and even to
0.05 mg/L when 0.05 mg/L pyrimethamine was used, indicating strong potentiation. 
These findings are in accordance with previous in-vitro studies assessing 
anti-Toxoplasma activity of various drug combinations (Harris et al., 1988; Derouin & 
Chastang, 1989). In these studies a limited amount of concentration combinations of 
pyrimethamine and sulphadiazine were investigated. By assessing more concentrations, 
the present study confirms the presence of synergism and shows that a ten-fold 
increment of the concentration of pyrimethamine reduced the IC50 of sulphamethoxa­
zole 1000 times. Because of the strongly potentiating effect of pyrimethamine, 
sulphonamides should remain effective at much lower doses than presently 
recommended. It is likely that dose reduction of sulphonamides will not reduce efficacy 
but will only reduce toxic side effects. Trimethoprim combined with a sulphonamide is 
not as potent as a combination with pyrimethamine. This is a reason to be cautious 
about reducing co-trimoxazole dosages in HIV patients on PCP prophylaxis. The 
protective effect of 960 mg co-trimoxazole daily is already questionable (Mallolas et al., 
1993) and further dose reduction may hamper concomitant Toxoplasma protection.
Pyrimethamine serves to trap cellular folates in the non-functional dihydro state. The 
accumulation of dihydrofolate reduces the effectiveness of the pyrimethamine. The 
effect of newly formed dihydrofolate is eliminated by the simultaneous application of 
a sulphonamide and by feeedback inhibition of accumulated dihydrofolate on its 
synthesis (Hitchings, 1973). This may explain why an increment in the concentration 
of pyrimethamine dramatically reduces the need for a sulphonamide with similar effect 
on T. gondii. The affinity of Toxoplasma D H FR  for trimethoprim is less compared with 
pyrimethamine (Chio et al., 1993). This may explain the observation that the
3.ni\-Toxoplasma effect of the combination trimethoprim-sulphamethoxazole is not as 
dose dependent.
The present findings confirm the suggestion of other authors (Harris et al., 1988) that 
the dose of pyrimethamine may be too high for the treatment of T. gondii infection. 
When haematological toxicity occurs during pyrimethamine treatment, concomitant use 
of folinic acid will not reduce the effectiveness of the anti-Toxoplasma therapy. This is
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in contrast with a report on the treatment of P. carinii pneumonia in AIDS patients 
with trimethoprim-sulphamethoxazole, where adjunctive folinic acid was associated 
with increased therapeutic failure (Safrin, Lee & Sande, 1994).
At present, the recommended concentrations of sulphonamides, when co­
administered with pyrimethamine or trimethoprim, do not account for the poten­
tiating effect of the combination and may therefore be too high. This could lead to 
unnecessary toxicity in HIV infected patients. However, the present data were obtained 
by in-vitro studies and their significance for the treatment of AIDS patients needs to 
be demonstrated. It should be noticed that serum drug concentrations may not be 
relevant when treating cerebral infections with drugs that differ in their penetration of 
the blood-brain barrier. Furthermore, the absorption of drugs may be variable, 
particularly as AIDS patients often have gastrointestinal pathology. Therefore more 
investigations are needed to validate these results in animals and in carefully designed 
pharmacokinetic studies in humans.
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